Clinical trial
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
NCT01125800 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 28, 2011
- Completion date
- October 31, 2014
- Enrollment
- 76 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.